B-Type Natriuretic Peptides and Echocardiographic Measures of Cardiac Structure and Function
Richard W. Troughton, MB, ChB, PhD, FRACP*,
A. Mark Richards, MD, PhD, DSc, FRACP
University Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand
* Reprint requests and correspondence: Dr. Richard W. Troughton, University Department of Medicine, University of Otago, Christchurch, PO Box 4345, Christchurch, New Zealand (Email: richard.troughton{at}cdhb.govt.nz).
Echocardiography and the B-type natriuretic peptides (BNPs) provide powerful incremental assessment of cardiac function, clinical status, and outcome across the spectrum of cardiac disease. There is strong evidence to support their integrated use in the diagnosis and management of cardiovascular disease. Amino-terminal pro-B-type natriuretic peptide (NT-proBNP) or BNP may guide more effective use of echocardiography in screening for asymptomatic left ventricular dysfunction; Doppler echocardiography improves the accuracy of heart failure diagnosis in the setting of intermediate BNP or NT-proBNP levels. Combined assessment of peptides and echocardiography provides more powerful stratification of risk across all stages of heart failure, and integrated use of both tests may identify subjects with valvular disease at greatest risk for progression and guide decision-making for timely intervention.
Key Words: natriuretic peptides echocardiography left ventricular function Doppler echocardiography
|
Abbreviations and Acronyms
| | aa = amino acid | | ADHF = acute decompensated heart failure | | BNP = B-type natriuretic peptide | | E/Ea = transmitral early filling velocity/early diastolic annular velocity | | LVEDP = left ventricular end diastolic pressure | | LVEF = left ventricular ejection fraction | | LVH = left ventricular hypertrophy | | NT-proBNP = amino-terminal pro-B-type natriuretic peptide | | PCWP = pulmonary capillary wedge pressure | | RV = right ventricle |
|
|